Valérie Picard

TL;DR: It is suggested that intensified treatment of genomically aggressive localized prostate cancer may improve cure rates and numerous molecular aberrations were prognostic for disease recurrence, including several DNA methylation events, and a signature comprised of these aberration outperformed well-described prognostic biomarkers.

TL;DR: Ultra-deep total RNA-seq on 144 tumors with rich clinical annotation revealed a linear transcriptomic subtype associated with the aggressive intraductal carcinoma sub-histology and a fusion profile that differentiates localized from metastatic disease.

TL;DR: A novel concept is posit in IDC/CA+ prostate cancer, "nimbosus" (gathering of stormy clouds, Latin), which manifests as increased metastatic capacity and lethality, which is associated with a constellation of genomic instability, SChLAP1 expression, and hypoxia.

TL;DR: MAGE‐A9 is a target of choice for bladder cancer immunotherapy as it is expressed in 60% of bladder tumors, predominantly high‐grade tumors, and at higher frequency in pTis and metastatic tumors.

TL;DR: The results show that MAGE‐A9 is frequently expressed in superficial bladder cancer and could be a relevant target for immunotherapy or chemoimmunotherapy because its expression can be induced by chemotherapeutic drugs.